A 12-month study evaluated the efficacy and safety of the drug candidate in adults with mild, moderate, and severe OSA.| Sleep Review
Top-line results are expected later this month.| Sleep Review
Alkermes’ alixorexton met primary and key secondary endpoints in a phase 2 trial for narcolepsy type 1, showing dose-dependent improvements.| Sleep Review
Takeda’s investigational orexin-2 receptor agonist oveporexton met all endpoints in two phase 3 trials for narcolepsy type 1.| Sleep Review